Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 13/20 | 0.59 |
| ▸ | F2 | P00734 | 4/20 | 0.59 |
| ▸ | KLK1 | P06870 | 4/20 | 0.59 |
| ▸ | TMPRSS15 | P98073 | 15/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7518598 | 1.00 | PRSS1 (0.59) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3245126 | 0.91 | PRSS1 (0.66) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL7304838 | 0.91 | PRSS1 (0.66) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3237141 | 0.90 | PRSS1 (0.67) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3241353 | 0.85 | PRSS1 (0.69) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3237873 | 0.85 | PRSS1 (0.72) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL7305539 | 0.85 | PRSS1 (0.72) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL5573460 | 0.85 | PRSS1 (0.56) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3241819 | 0.84 | PRSS1 (0.65) | PRSS1F2KLK1TMPRSS15 | |
| SCHEMBL3237729 | 0.83 | PRSS1 (0.69) | PRSS1F2KLK1TMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128315-A1 | Leukotriene B4 antagonist compounds and method for treatment | NAKAI HISAO (JP) | 2002-09-12 | — | — | US | claimed |
| EP-0703216-A1 | Amidinophenol derivatives as protease inhibitors | ONO PHARMACEUTICAL CO., LTD. (JP) | 1996-03-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128315-A1 | Leukotriene B4 antagonist compounds and method for treatment | LTB4R2, LTB4R, LTA4H | PRSS1 146/4885F2 182/4885KLK1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.